2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002

Vasogen Announces Third Quarter 2006 Results

Mississauga, Ontario - October 12, 2006

Vasogen Inc. (NASDAQ:VSGN; TSX:VAS, today reported the results of operations for the third quarter of 2006. Comparative figures relate to the three- and nine-month periods ended August 31, 2006, and to the three- and nine-month periods ended August 31, 2005. All dollar amounts referenced herein are in Canadian dollars, unless otherwise stated.

At August 31, 2006, our cash and cash equivalents, restricted cash, and marketable securities held to maturity totaled $25.6 million, compared with $85.2 million at November 30, 2005.

As of October 1, 2006, the outstanding principal balance of our convertible notes has been reduced to US$10.0 million. Beginning September 1, 2006, we have been required, under the terms of the convertible notes, to maintain a balance of cash, including restricted cash, and marketable securities equal to 110% of the convertible notes outstanding. We have satisfied this cash test at all times since it came into effect.

The loss for the third quarter of 2006 was $14.6 million, or $0.15 per share, compared to a loss of $24.1 million, or $0.30 per share, in the third quarter of 2005. For the nine months ended August 31, 2006, the loss was $56.3 million, or $0.64 per share, compared to a loss of $69.0 million, or $0.87 per share, for the comparable period in 2005. The loss has decreased as a result of a reduction in the costs associated with our phase III clinical programs and has been partially offset by expenses associated with the senior convertible notes. The difference between cash used in operations and our accounting loss includes such non-cash items as stock option grant expense, amortization expense, accretion and amortization of costs associated with the senior convertible notes payable, offset by payment of accrued expenses related to our recently completed phase III clinical trials.

Research and development expenditures were $7.4 million in the third quarter of 2006, compared to $17.2 million in the third quarter of 2005. For the nine months ended August 31, 2006, these expenditures were $29.8 million, compared to $54.7 million for the comparable period in 2005. The majority of the decrease in our R&D expense for the three months and nine months ended August 31, 2006, when compared with the same periods in 2005, resulted from a significant reduction in the clinical trial activities relating to our phase III programs.

General and administration expenditures were $3.8 million for the third quarter of 2006, compared to $5.2 million for the third quarter of 2005. For the nine months ended August 31, 2006, these expenditures were $14.3 million, compared to $16.6 million for the comparable period in 2005.

Highlights

• On September 13, 2006, new data were presented from the 2,400-patient ACCLAIM trial of our Celacade technology in chronic heart failure that showed the average days spent in hospital for cardiovascular cause was reduced by 32% in a prime heart failure target population, consisting of New York Heart Association (NYHA) Class II-IV non-ischemic cardiomyopathy patients, characterized as having no prior history of heart attack, and Class II patients with ischemic heart failure (n=1,305 patients, p=0.01). The results were presented by Guillermo Torre-Amione, MD, PhD, at the 10th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) in Seattle, Washington. Chronic heart failure is estimated to cost the healthcare system $25 billion annually in the U.S., and recurring hospitalizations are the major cost driver.
  
  
• On September 3, 2006, Dr. Torre-Amione also presented new ACCLAIM data at a late-breaking clinical trial Hot Line Session of the World Congress of Cardiology 2006 (WCC) in Barcelona, Spain. In a combined analysis of NYHA Class II-IV non-ischemic cardiomyopathy patients, characterized as having no prior history of heart attack, as well as Class II patients with ischemic etiology, Celacade demonstrated a 31% reduction in the risk of death or first cardiovascular hospitalization compared to placebo (n=1,305 patients, 391 events, p=0.0003). New data also showed that Celacade significantly reduced the risk of death or first cardiovascular hospitalization by 26% in a subgroup of patients with no prior history of heart attack at baseline (n=919 patients, 243 events, p=0.02). As previously reported, in the subgroup of patients with NYHA Class II heart failure at baseline, Celacade was also shown to significantly reduce the risk of death or first cardiovascular hospitalization by 39% (n=689 patients, 216 events, p=0.0003).
• Consistent with the impact of Celacade on the risk of mortality and morbidity in major subgroups within the ACCLAIM trial was the finding of a significant improvement in quality of life (as measured by the Minnesota Living with Heart Failure Questionnaire) for the intent-to-treat study population (n=2,400 patients, p=0.04). Celacade was also shown to be safe and well tolerated, and there were no significant between-group differences for any serious adverse events.

As previously announced, a conference call and audio web cast will be conducted on October 12, 2006, at 4:30 p.m. Eastern Time. The conference call may be accessed by calling 416-695-6130 or 1-800-766-6630, ten minutes prior to the call. An audio webcast of the event will also be available at www.vasogen.com. A re-broadcast of the conference call may be accessed by calling 416-641-2135 or 1-800-293-6441, pin code: 2017, and will also be available at www.vasogen.com.

About Vasogen
Vasogen is focused on the research and commercial development of technologies targeting the chronic inflammation underlying cardiovascular and neurological disease. Vasogen’s Celacade technology is in late-stage development for the treatment of chronic heart failure. The recently completed phase III ACCLAIM trial assessed the impact of Celacade on reducing the risk of mortality and morbidity in patients with Class II-IV systolic heart failure. Vasogen is also developing a new class of drugs for the treatment of neuro-inflammatory and neuro-vascular disorders. VP025, which is entering phase II clinical development, is the lead product candidate from this new class of drugs.

Certain statements in this press release and upcoming conference call and webcast constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995. These statements may include, without limitation, summary statements relating to results of the ACCLAIM trial in patients with chronic heart failure, plans to advance the development of Celacade™, statements concerning our partnering activities and health regulatory submissions, strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management. In some cases, you can identify forward-looking statements by terminology such as “may”, “will”, “should”, “expects”, “plans”, “anticipates”, “believes”, “estimated”, “predicts”, “potential”, “continue”, “intends”, “could”, or the negative of such terms or other comparable terminology. A number of assumptions were made by us in the preparation of these forward-looking statements, including assumptions about the nature, size and accessibility of the market for Celacade in the treatment of chronic heart failure, particularly in Europe, the regulatory approval process leading to commercialization and the availability of capital on acceptable terms to pursue the development of Celacade. You should not place undue reliance on our forward-looking statements which are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances or events to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the outcome of further analysis of the ACCLAIM trial results, the requirement or election to conduct additional clinical trials, delays or setbacks in the regulatory approval process, securing and maintaining corporate alliances, the need for additional capital and the effect of capital market conditions and other factors on capital availability, the potential dilutive effects of any financing, including the convertible notes we issued in October 2005, risks associated with the outcome of our research and development programs, the adequacy, timing and results of our clinical trials, competition, market acceptance of our products, the availability of government and insurance reimbursements for our products, the strength of intellectual property, reliance on subcontractors and key personnel, losses due to fluctuations in the U.S.-Canadian exchange rate, and other risks detailed from time to time in our public disclosure documents or other filings with the Canadian and U.S. securities commissions or other securities regulatory bodies. Additional risks and uncertainties relating to our Company and our business can be found in the “Risk Factors” section of our Annual Information Form and Form 40-F for the year ended November 30, 2005, as well as in our later public filings. The forward-looking statements are made as of the date hereof, and we disclaim any intention and have no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Unless otherwise indicated, numerical values indicating the statistical significance ("p-values") of results included in this document are based on analyses that do not account for endpoint multiplicity.

View Entire Press Release with Financials